Literature DB >> 23008298

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Ahmad A Tarhini, John M Kirkwood.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23008298     DOI： 10.1200/JCO.2012.44.9975

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit.

Authors:  Ahmad A Tarhini; Yan Lin; Hui-Min Lin; Priyanka Vallabhaneni; Cindy Sander; William LaFramboise; Lana Hamieh
Journal:  Oncoimmunology       Date:  2016-09-19       Impact factor: 8.110

3.  A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Authors:  Ahmad A Tarhini; Theofanis Floros; Hui-Min Lin; Yan Lin; Zahra Rahman; Madeeha Ashraf; Priyanka Vallabhaneni; Cindy Sander; Uma N M Rao; Monica Panelli; William A LaFramboise; John M Kirkwood
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

Review 4.  Adjuvant Therapy for Melanoma.

Authors:  Aya Agha; Ahmad A Tarhini
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 5.  Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

Authors:  Theofanis Floros; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

6.  A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

Authors:  Ahmad A Tarhini; Yan Lin; Oladapo Yeku; William A LaFramboise; Madeeha Ashraf; Cindy Sander; Sandra Lee; John M Kirkwood
Journal:  J Transl Med       Date:  2014-01-23       Impact factor: 5.531

Review 7.  Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.

Authors:  Atik Badshah Shaikh; Fangfei Li; Min Li; Bing He; Xiaojuan He; Guofen Chen; Baosheng Guo; Defang Li; Feng Jiang; Lei Dang; Shaowei Zheng; Chao Liang; Jin Liu; Cheng Lu; Biao Liu; Jun Lu; Luyao Wang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-04-06       Impact factor: 5.923

8.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Authors:  Stefan S Bielack; Sigbjørn Smeland; Jeremy S Whelan; Neyssa Marina; Gordana Jovic; Jane M Hook; Mark D Krailo; Mark Gebhardt; Zsuzsanna Pápai; James Meyer; Helen Nadel; R Lor Randall; Claudia Deffenbaugh; Rajaram Nagarajan; Bernadette Brennan; G Douglas Letson; Lisa A Teot; Allen Goorin; Daniel Baumhoer; Leo Kager; Mathias Werner; Ching C Lau; Kirsten Sundby Hall; Hans Gelderblom; Paul Meyers; Richard Gorlick; Reinhard Windhager; Knut Helmke; Mikael Eriksson; Peter M Hoogerbrugge; Paula Schomberg; Per-Ulf Tunn; Thomas Kühne; Heribert Jürgens; Henk van den Berg; Tom Böhling; Susan Picton; Marleen Renard; Peter Reichardt; Joachim Gerss; Trude Butterfass-Bahloul; Carol Morris; Pancras C W Hogendoorn; Beatrice Seddon; Gabriele Calaminus; Maria Michelagnoli; Catharina Dhooge; Matthew R Sydes; Mark Bernstein
Journal:  J Clin Oncol       Date:  2015-06-01       Impact factor: 44.544

9.  Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Authors:  Ahmad A Tarhini; Sandra J Lee; F Stephen Hodi; Uma N M Rao; Gary I Cohen; Omid Hamid; Laura F Hutchins; Jeffrey A Sosman; Harriett M Kluger; Zeynep Eroglu; Henry B Koon; Donald P Lawrence; Kari L Kendra; David R Minor; Carrie B Lee; Mark R Albertini; Lawrence E Flaherty; Teresa M Petrella; Howard Streicher; Vernon K Sondak; John M Kirkwood
Journal:  J Clin Oncol       Date:  2019-12-27       Impact factor: 50.717

10.  Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

Authors:  Janet Retseck; Robert VanderWeele; Hui-Min Lin; Yan Lin; Lisa H Butterfield; Ahmad A Tarhini
Journal:  J Immunother Cancer       Date:  2016-06-21       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.